Home > Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder
Neuroimmunology

Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder

Published Online: June 18th 2020

Sean Pittock (Mayo Clinic College of Medicine, Rochester, MN, USA) shared with us his expert insights from the phase 3 PREVENT study, a randomized controlled trial of eculizumab in AQP4 antibody-positive participants with neuromyelitis optica (ClinicalTrials.gov Identifier: NCT01892345), including a sub analysis he presented on eculizumab monotherapy.

Questions
1. Could you give us an overview of neuromyelitis optica spectrum disorder (NMOSD), its pathophysiology and manifestations? (
0:05)
2. What are the unmet needs in the treatment of NMOSD? (
1:12)
3. What is the rationale for the use of eculizumab in the treatment of NMOSD? (
2:23)
4. Could you tell us a little about the aims and design of the PREVENT study? (
3:47)
5. What have been the major efficacy and safety findings of the study? (
4:56)
6. What can you tell us about eculizumab monotherapy in NMOSD based on the PREVENT subgroup analysis you presented as an ePoster in the late-breaking session at EAN 2020? (
6:20)

Speaker disclosure: Sean Pittock reports grants from Grifols, other from Euroimmun, grants from NIH, grants, personal fees and non-financial support from Guthy Jackson Charitable Foundation, grants from AEA (Autoimmune Encephalitis Alliance), grants, personal fees, non-financial support and other from MedImmune, Inc., other from Astellas, personal fees from UCB, Inc., personal fees from Hoffman/LaRoche AG, grants, personal fees, non-financial support and other from Alexion Pharmaceuticals, Inc., outside the submitted work; In addition, Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) – Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, a patent Patent# 9,891,219B2 (Application#12-573942) – Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued, a patent GFAP-IgG pending, a patent Septin-5-IgG pending, a patent MAP1B-IgG pending, a patent Kelch-like protein 11 pending, and a patent PDE10A pending.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.

Share this Video
Related Videos In Neuroimmunology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72